Bank of America
BLCM

Bank of America’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Bank of America’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10
Closed – – 8644
2022
Q1 		$0 Sell
10
-16
-62% -$26 ﹤0.01% 9004
2021
Q4 		$0 Buy
+26
New +$52 ﹤0.01% 8860
2021
Q2 		– Sell
-26
Closed – – 8255
2021
Q1 		$0 Buy
+26
New +$113 ﹤0.01% 7916
2020
Q4 		– Sell
-681
Closed -$4K – 7474
2020
Q3 		$4K Sell
681
-319
-32% -$2.16K ﹤0.01% 6633
2020
Q2 		$7K Hold
1,000
– – ﹤0.01% 6521
2020
Q1 		$5K Hold
1,000
– – ﹤0.01% 6508
2019
Q4 		$13K Sell
1,000
-260
-21% -$2.4K ﹤0.01% 6609
2019
Q3 		$14K Sell
1,260
-4,058
-76% -$53K ﹤0.01% 6657
2019
Q2 		$91K Sell
5,318
-5,871
-52% -$159K ﹤0.01% 6059
2019
Q1 		$377K Sell
11,189
-2,289
-17% -$76.5K ﹤0.01% 5196
2018
Q4 		$393K Buy
13,478
+12,576
+1,394% +$558K ﹤0.01% 5091
2018
Q3 		$56K Sell
902
-317
-26% -$21.5K ﹤0.01% 6170
2018
Q2 		$89K Sell
1,219
-379
-24% -$29.5K ﹤0.01% 5854
2018
Q1 		$105K Buy
1,598
+580
+57% +$43.8K ﹤0.01% 5719
2017
Q4 		$86K Sell
1,018
-398
-28% -$39K ﹤0.01% 5811
2017
Q3 		$163K Buy
1,416
+551
+64% +$58K ﹤0.01% 5479
2017
Q2 		$101K Buy
865
+161
+23% +$20K ﹤0.01% 5609
2017
Q1 		$87K Buy
704
+132
+23% +$17.3K ﹤0.01% 5677
2016
Q4 		$78K Buy
572
+363
+174% +$64.4K ﹤0.01% 5741
2016
Q3 		$41K Sell
209
-69
-25% -$11.9K ﹤0.01% 5811
2016
Q2 		$36K Buy
278
+203
+271% +$22.6K ﹤0.01% 5980
2016
Q1 		$7K Sell
75
-2,568
-97% -$280K ﹤0.01% 6498
2015
Q4 		$536K Buy
2,643
+1,440
+120% +$258K ﹤0.01% 4775
2015
Q3 		$175K Buy
1,203
+119
+11% +$21.8K ﹤0.01% 5398
2015
Q2 		$231K Sell
1,084
-54
-5% -$13.2K ﹤0.01% 5176
2015
Q1 		$264K Buy
1,138
+1,128
+11,280% +$273K ﹤0.01% 4752
2014
Q4 		$2K Buy
+10
New +$2.15K ﹤0.01% 7503

Other funds holding BLCM

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America's BLCM Position: Q2 2022 in Review

Bank of America sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2022, closing a stake of 10 shares.

Bank of America first reported a position in BLCM in Q4 2014 and held it in 27 quarters. The position peaked at $536K in Q4 2015. 30 funds tracked by Wall St. Rank hold BLCM as of Q2 2022.

  • Bank of America reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Bank of America sold 10 Bellicum Pharmaceuticals, Inc. shares in Q2 2022.
  • Bank of America first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 27 quarters.
  • Bank of America's Bellicum Pharmaceuticals, Inc. position peaked at $536K in Q4 2015.
  • 30 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2022.

Based on Bank of America's 13F filing for Q2 2022, filed 12 Aug 2022.